CoChat
Sign Up
PreprintCited by 533Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 394 of the 394 references it cites were found in a registry or an index.

Genetics and biology of pancreatic ductal adenocarcinoma

Open access
Ying, Haoqiang, Dey, Prasenjit, Yao, Wantong, Kimmelman, Alec C., Draetta, Giulio F., Maitra, Anirban, DePinho, Ronald A.·2016·Genes & Development
DOI 10.1101/gad.275776.115
Open this paper in CoChat — free account

Abstract

With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. During the past decade, the comprehensive atlas of genomic alterations, the prominence of specific pathways, the preclinical validation of such emerging targets, sophisticated preclinical model systems, and the molecular classification of PDAC into specific disease subtypes have all converged to illuminate drug discovery programs with clearer clinical path hypotheses. A deeper understanding of cancer cell biology, particularly altered cancer cell metabolism and impaired DNA repair processes, is providing novel therapeutic strategies that show strong preclinical activity. Elucidation of tumor biology principles, most notably a deeper understanding of the complexity of immune regulation in the tumor microenvironment, has provided an exciting framework to reawaken the immune system to attack PDAC cancer cells. While the long road of translation lies ahead, the path to meaningful clinical progress has never been clearer to improve PDAC patient survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.275776.115

Cites

394 of 394 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 392 references

Research works printed but not linked: 1

  1. Kloppel G . 2000. WHO classification of tumours. IARC Press, Lyon, France.

Cited by

Sorted by citations

Items 501–533 of 533

Related

See all

Metadata

Authors
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Dana-Farber Cancer Institute (US)
ORCID
Venue
Genes & Development
Publisher
Cold Spring Harbor Laboratory
Published
2016-02-15
Volume
30
Issue
4
Pages
355-385
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
DOI
10.1101/gad.275776.115
OpenAlex
W4295846302
Cited by
527
References
392
Citations by year
2026: 20 · 2025: 33 · 2024: 44 · 2023: 68 · 2022: 56 · 2021: 75 · 2020: 57 · 2019: 48 · 2018: 51 · 2017: 59 · 2016: 16
Type
posted content
Language
en
Open access
Licence
cc-by-nc
Locations
  • Genes & Development (publishedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Sheikh Ahmed Center for Pancreatic Cancer Research
  • Pancreatic Cancer Moon Shot at the University of Texas MD Anderson Cancer Center
  • University of Texas Star Award (W81XWH-14-1-0429)
  • Department of Defense (U01DK108328, U01CA196403)
  • Odyssey Fellowship (Anne Eastland Spears Fellowship in GI Cancer Research)
  • University of Texas MD Anderson Cancer Center (RSG-13-298-01-TBG)
  • American Cancer Society (R01GM095567, R01CA157490, R01CA188048)
  • National Institutes of Health (14-90-25-DRAE, P01CA117969)
  • American Association for Cancer Research (W81XWH-11-1-0418)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
pancreatic ductal adenocarcinoma, cancer genomics, molecular classification, cancer metabolism, DNA repair, tumor microenvironment, cancer immunotherapy, drug discovery, obesity, metabolic syndrome, preclinical models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review